Aims-To investigate and characterise the appearance of non-transferrin bound iron (NTBI) in the serum ofpatients after cytotoxic chemotherapy and to compare this with the onset and duration of neutropenia. Method-Non-transferrin bound iron was measured by a bleomycin assay in patients undergoing intensive chemotherapy for treatment of acute leukaemia or lymphoma. Results-NTBI was detected after 26 of 27 courses of chemotherapy and lasted for a mean of 14-5 days. The presence of NTBI correlated with the serum iron binding saturation, but not with serum ferritin. Neutropenia occurred after all courses of chemotherapy and lasted for a mean of 20-0 days. NTBI and neutropenia occurred concurrently after 23 courses of chemotherapy, and had a mean joint duration of 9'5 days. Conclusions-NTBI is consistently present in the serum of patients after cytotoxic chemotherapy, often at the same time as the patient is neutropenic. This may be an additional risk factor for the development of infective episodes after chemotherapy.
In patients with chronic iron overload serum transferrin becomes fully saturated and an abnormal iron fraction can appear in the serum. This effect has been reported in several conditions including idiopathic haemachromatosis,l and in patients with thalassaemia trait and chronic active hepatitis. 2 Patients with acute leukaemia have been reported to have high serum iron concentrations and high levels of transferrin saturation. '4 Intensive cytotoxic chemotherapy would be expected to release intracellular iron from cells undergoing cytolysis. This could result in total saturation of serum iron binding capacity followed by the appearance of a circulating non-transferrin bound iron (NTBI) fraction.
The presence of iron is essential for the growth of almost all bacteria, and normally serum iron is relatively unavailable to bacteria as it is bound to transferrin or ferritin. The presence of NTBI in the serum of patients after cytotoxic chemotherapy would therefore be an additional risk factor (to that of neutropenia) for the development of infective episodes.
To investigate and characterise the appearance of NTBI after chemotherapy, NTBI together with serum iron, serum total iron binding capacity, and serum ferritin were measured in patients undergoing cytotoxic chemotherapy for haematological malignancies.
Methods
Patients with acute leukaemia or lymphoma undergoing combination cytotoxic chemotherapy for either remission induction or consolidation were studied. The study was carried out at Dudley Road Hospital, Birmingham. All patients received conventional doses of chemotherapy. The patients were venesected at least three times a week for full blood counts, and serum samples were taken routinely for iron studies at the same time. A serum sample was taken from all patients before the start of chemotherapy. Full blood counts were performed on a Technicon H*1 analyser (Technicon Corporation, New York, USA). For this study neutropenia was defined as an absolute neutrophil count of less than 0-5 x 109/1. The follow up period ended when either a further course of chemotherapy was given, two consecutive samples were negative for NTBI after the end of the neutropenic period, or a total of 55 days had elapsed, whichever was the shorter. A total of 10 patients were studied during 27 courses of combination chemotherapy. Non-transferrin bound iron and neutropenia after cytotoxic chemotherapy 
Discussion
This study shows that NTBI is consistently present in the serum of patients after cytotoxic chemotherapy; often at the same time as the patient is neutropenic. The appearance of NTBI corresponds to the saturation of serum total iron binding capacity, and shows no correlation to the level of serum ferritin. The study confirms a previously reported finding that NTBI is present in the serum of patients after intensive cytotoxic chemotherapy for the treatment of acute leukaemia.7 Unlike this previous report, however, we did not detect NTBI before the start of chemotherapy.
Caroline et al 3 showed not only that patients with acute leukaemia had high and often fully saturated iron binding capacity but that their serum enhanced the growth of candida in vitro compared with normal serum. A further study reported differences in survival in acute lymphoblastic leukaemia between patients with a low versus high transferrin saturation.8 In this study patients with a transferrin saturation of less than 36% were found to have a lower death rate than those with a saturation greater than this. It was not, however, possible to say from this study whether infection accounted for some of the differences in survival.
There are several reasons why an NTBI fraction might lead to an increased incidence of infections. Firstly, iron is essential for the growth of almost all bacteria, and, under normal circumstances, serum iron is relatively unavailable to bacteria as it is bound to transferrin or ferritin. Supportive evidence for this comes from the many studies showing that the in vitro bacteriostatic effect of serum is lost when transferrin is saturated.9 The importance of iron for bacterial growth is further highlighted by some pathogenic species in which plasmids associated with increased virulence code for sideropores that facilitate iron uptake.
I
Evidence has been summarised which suggests that the host's ability to fight infection may be impaired in several ways by high concentrations of iron." 12 In particular, in vitro lymphocyte proliferation may be reduced when transferrin saturation nears 100%13; and phagocytosis of bacteria by neutrophils is reduced after exposure to iron salts. '4 Another mechanism by which NTBI may be detrimental to the leukaemic patient is by free radical mediated tissue damage. It has been suggested that NTBI may mediate tissue damage by the formation of highly reactive hydroxyl radicals from superoxide and hydrogen peroxide. Also, it is known that certain chemotherapeutic agents, such as doxorubicin, promote the generation of both superoxide and hydrogen peroxide. 7 An increased susceptibility to infection caused by the presence of NTBI would be at least partly masked by the risk of infection associated with neutropenia. During the period of observation in this study 26 pyrexial episodes were recorded, of which 16 were associated with a bacterial isolate. Due to the large overlap of the neutropenic period with the duration of detectable NTBI the relative contributions of either to the infections was difficult to analyse. With the advent of recombinant haemopoietic growth factors, however, such as granulocyte colony stimulating factor (G-CSF), which can shorten periods of neutropenia, other potential risk factors for infection such as NTBI may become clinically significant.
We believe that further work in this area is justified to investigate the theory that NTBI contributes to the increased incidence of infection seen after cytotoxic chemotherapy.
